---
title: "特朗普威脅英國國家醫療服務體系面臨更高的藥品價格"
description: "唐納德·特朗普正在施壓包括葛蘭素史克和阿斯利康在內的主要製藥公司，要求它們降低美國的藥品價格。他建議這些公司應通過提高國外的價格來彌補美國價格的降低，這對英國國家醫療服務體系（NHS）構成潛在威脅"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/251061482.md"
published_at: "2025-07-31T20:33:26.000Z"
---

# 特朗普威脅英國國家醫療服務體系面臨更高的藥品價格

> 唐納德·特朗普正在施壓包括葛蘭素史克和阿斯利康在內的主要製藥公司，要求它們降低美國的藥品價格。他建議這些公司應通過提高國外的價格來彌補美國價格的降低，這對英國國家醫療服務體系（NHS）構成潛在威脅

Donald Trump is pressuring the world’s biggest drug makers to raise prices outside of the US in a threat to the NHS. The US president has written to pharmaceutical companies including Britain’s GSK and AstraZeneca to demand they lower prices for Americans, suggesting they should pay for it by charging higher fees abroad. It raises the threat of hig...

### Related Stocks

- [GSK.UK - 葛蘭素史克](https://longbridge.com/zh-HK/quote/GSK.UK.md)
- [GSK.US - 葛蘭素史克](https://longbridge.com/zh-HK/quote/GSK.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| GSK Recieves Approval For Exdensur From The European Commission | GSK plc :GSK PLC - EXDENSUR APPROVED BY THE EUROPEAN COMMISSIONGSK PLC - EXDENSUR APPROVED BY THE EUROPEAN COMMISSION | [Link](https://longbridge.com/zh-HK/news/276102835.md) |
| GSK Begins Up to GBP450 Million Share Buyback Tranche | GSK Begins Up to GBP450 Million Share Buyback Tranche | [Link](https://longbridge.com/zh-HK/news/276103252.md) |
| Exdensur approved in EU for severe asthma and CRSwNP | GSK has received European Commission approval for Exdensur (depemokimab), the first ultra-long-acting biologic for sever | [Link](https://longbridge.com/zh-HK/news/276226507.md) |
| Berenberg Bank Keeps Their Hold Rating on GlaxoSmithKline (GSK) | Berenberg Bank analyst Kerry Holford has maintained a Hold rating on GlaxoSmithKline (GSK) with a price target of £20.00 | [Link](https://longbridge.com/zh-HK/news/276103203.md) |
| GSK Begins Fourth Tranche Of Up To GBP 0.45 Bln Share Buyback Under GBP 2 Bln Programme | British drug major GSK plc has announced the commencement of the fourth tranche of its £2 billion share buyback program, | [Link](https://longbridge.com/zh-HK/news/276103384.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。